Antibody Therapies for Large B-Cell Lymphoma

Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Novo, Mattia, Santambrogio, Elisa, Frascione, Pio Manlio Mirko, Rota-Scalabrini, Delia, Vitolo, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141264/
https://www.ncbi.nlm.nih.gov/pubmed/34040344
http://dx.doi.org/10.2147/BTT.S281618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141264/
https://www.ncbi.nlm.nih.gov/pubmed/34040344
http://dx.doi.org/10.2147/BTT.S281618

Ejemplares similares